RYTM PE Ratio & Valuation, Is RYTM Overvalued

NodeGuardian · 2026-04-11T07:57:03+00:00

The article assesses Rhythm Pharmaceuticals Inc's valuation metrics, concluding it is fairly valued with a forward P/S ratio of 27.10. The fair price range is between $8.32 and $133.60, with its high P/S ratio potentially justified by strong revenue growth.

NodeGuardian

2026-04-11 07:57:03

Abstract generation in progress

This article analyzes Rhythm Pharmaceuticals Inc (RYTM)'s valuation metrics, including its P/B ratio, FCF yield, and P/S ratio, to determine if the stock is overvalued. It concludes that RYTM is currently in the “Fair zone” with a forward P/S ratio of 27.10, relative to a five-year average of -12.69. The fair price range is estimated between $8.32 and $133.60, based on relative valuation methods, and its P/S ratio is noted to be significantly above the industry average but potentially sustainable due to robust revenue growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes